本文已被:浏览 448次 下载 57次
投稿时间:2024-12-11 网络发布日期:2025-02-20
投稿时间:2024-12-11 网络发布日期:2025-02-20
中文摘要: 目的 探讨血尿酸/白蛋白比值(UAR)与急性非ST段抬高心肌梗死(NSTEMI)患者经皮冠状动脉介入治疗(PCI)术后发生无复流/慢血流的相关性,分析其预测价值。方法 回顾性分析南京医科大学附属苏州医院2021年3月至2024年2月收治的324例在入院24 h内接受PCI的NSTEMI患者的资料。采用心肌梗死溶栓治疗(TIMI)血流评分来描述血流情况,TIMI 0~2级为无复流/慢血流组(39例),TIMI 3级为正常血流(285例)组。对正常血流和无复流/慢血流患者基线特征、病变特征进行比较。采用多因素logistic回归分析影响NSTEMI患者无复流/慢血流发生的独立影响因素。绘制ROC曲线分析UAR对无复流/慢血流发生的预测价值。结果 多因素logistic分析显示,UAR、尿素、SYNTAX评分为无复流/慢血流发生的独立影响因素(P<0.05)。ROC曲线显示,UAR预测无复流/慢血流发生的曲线下面积(AUC)为0.869,明显高于高于尿素(AUC=0.676)和SYNTAX评分(AUC=0.860)。结论 UAR是NSTEMI患者介入治疗后无复流/慢血流的独立预测因子,临床中可使用UAR来预测NSTEMI患者PCI术后无复流/慢血流的发生风险。
中文关键词: 急性非ST段抬高心肌梗死 溶栓治疗 介入治疗 尿酸/白蛋白比值
Abstract:Objective To investigate the correlation between the uric acid/albumin ratio (UAR) and the occurrence of no-reflow/slow-flow after percutaneous coronary intervention (PCI) in patients with acute non-ST segment elevation myocardial infarction (NSTEMI), and to analyze its predictive value. Methods A retrospective analysis was conducted on the data of 324 NSTEMI patients who underwent PCI within 24 hours of admission at Suzhou Hospital Affiliated to Nanjing Medical University between March 2021 and February 2024. The thrombolysis in myocardial infarction (TIMI) flow score was used to describe blood flow. A TIMI score of 0-2 was categorized as the no-reflow/slow-flow group (39 cases), and a TIMI score of 3 as the normal flow group (285 cases). Baseline characteristics and lesion characteristics of patients with normal flow and patients with no-reflow/slow-flow were compared.Multivariate logistic regression was used to analyze the independent factors affecting the occurrence of no-reflow/slow-flow in NSTEMI patients.ROC curve was plotted to analyze the predictive value of UAR for the occurrence of no-reflow/slow-flow. Results Multivariate logistic analysis showed that UAR, urea and SYNTAX score were independent influencing factors of no-reflow/slow-flow occurrence (P<0.05). The ROC curve showed that the area under the curve (AUC) for UAR was 0.869, significantly higher than that for urea (AUC=0.676) and SYNTAX score (AUC=0.860). Conclusion UAR is an independent predictor of no-reflow/slow-flow after PCI in NSTEMI patients. Clinically, UAR can be used to predict the risk of no-reflow/slow-flow in NSTEMI patients after PCI.
keywords: Acute non-ST segment elevation myocardial infarction Thrombolysis therapy Percutaneous coronary intervention Uric acid/albumin ratio
文章编号: 中图分类号:R541.4 R542.22 文献标志码:A
基金项目:江苏省卫生健康委员会科研项目(M2022042);苏州市心血管病重点实验室项目(SZS2024015)
附件
Author Name | Affiliation |
GONG Junrong, LI Yafei, DAI He, ZHU Fuyu, CHEN Wenting | Department of Cardiology, Suzhou Hospital Affiliated to Nanjing Medical University, Suzhou, Jiangsu 215000, China |
引用文本:
龚俊荣,李亚飞,戴贺,朱福雨,陈文婷.血尿酸/白蛋白比值与急性非ST段抬高心肌梗死PCI术后患者无复流/慢血流的预测价值[J].中国临床研究,2025,38(2):257-260.
龚俊荣,李亚飞,戴贺,朱福雨,陈文婷.血尿酸/白蛋白比值与急性非ST段抬高心肌梗死PCI术后患者无复流/慢血流的预测价值[J].中国临床研究,2025,38(2):257-260.